A multi-center Phase 2 trial in Japan involving SCA3 and SCA6 patients, underscoring the Stemchymal efficacy in different populations
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Adipose-derived stem cells-Steminent (Primary)
- Indications Spinocerebellar ataxias
- Focus Therapeutic Use
Most Recent Events
- 30 Apr 2025 New trial record
- 24 Apr 2025 According to a Steminent Biotherapeutics Media Release, result form this trial will be presented at the ISCT 2025 Annual Meeting in New Orleans in May.
- 24 Apr 2025 According to a Steminent Biotherapeutics Media Release, result form this trial were presented at the World Orphan Drug Congress (WODC) USA 2025 on April 23 in Boston.